Infecciones en el paciente inmunocomprometido (III). Diabetes mellitus, insuficiencia renal, cirrosis y enfermedad pulmonar obstructiva crónica

  1. Íñigo Pestaña, M. 1
  2. Pérez García, A. 1
  3. Falcón Abad, R. 1
  1. 1 Servicio de Microbiología Clínica y Parasitología, Clínica Universidad de Navarra, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2022

Título del ejemplar: Enfermedades infecciosas (VIII)

Serie: 13

Número: 56

Páginas: 3298-3307

Tipo: Artículo

DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Diabetes mellitus, chronic kidney failure, cirrhosis, and chronic obstructive pulmonary disease all have in common a high prevalence in the population worldwide, the fact that patients present with comorbidities (related amongst themselves), and alterations in immunity which, affecting the patient to a greater or lesser extent, entail a greater predisposition to infection. Patients affected by these diseases also have in common a need for frequent medical care that predisposes them even further not only to infection, but also for this infection to be caused by multidrug-resistant microorganisms. Appropriate care for these patients is essential in order to limit the onset of these infections, which significantly increase the emergence of complications and the mortality rate.

Referencias bibliográficas

  • Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW. IDF Diabetes Atlas: Global estimates of diabetes prevaence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-81.
  • Muller LMAJ, Gorter KJ, Hak E, Goudzaard WL, Schellevis FG, Hoepelman AIM. Increased risk of common infections in patients with type 1 and 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-8.
  • Pearson Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4(2):148-58.
  • Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26(2):510-3.
  • Knapp S. Diabetes and infection: in there a link? A mini-review. Gerontology. 2013;59(2):99-104.
  • Amstrong LR, Kammerer JS, Haddad M, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010-2017. BMJ Open Diabetes Res Care. 2020;8(1):e001275.
  • Sajid M, Akash H, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resis- tance and possible treatment strategies. Arch Microbiol. 2020;202(5): 953-65.
  • Mensa J, Soriano A, López-Suñé E, Llinares P, Barberán J, Zboromyrska, Y. Guía de terapéutica antimicrobiana 2021. 31ª ed. Marzo 2021.
  • Blanes JIM, Representatives of Spanish Society of Surgeons (ACS); Representatives of Spanish Society of Angiology and Vascu lar Surgery (SEACV); Representatives of Spanish Society of Emergency Medicine (SEMES); Spanish Internal Medicine Society (SEMI); Representatives of Spanish Society of Critical Care Medicine and Coronary Units (SEMICYUC), et al. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter. 2011;24(4):233-62.
  • Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-28.
  • Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64(7):1480-91.
  • Jha V, García García G, Iseki K, Li Z, Naicker S, Plattner B. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-27.
  • Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Ne- phrol. 2019;23(4):437-47.
  • McDonald HI, Thomas SL, Millett ER, Nitsch D. CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. Am J Kidney Dis. 2015;66(1):60-8.
  • Berns JS. Infection with antimicrobial-resistant microorganisms in dyalisis patients. Semin Dial. 2003;16(1):30-7.
  • Kumbar L, Yee J. Current concepts in hemodialysis vascular access infections. Adv Chronic Kidney Dis. 2019;26(1):16-22.
  • Cahuayme Zuniga LJ, Brust KB. Mycobacterial infections in patients with chronic kidney disease and kidney transplantation. Adv Chronic Kidney Dis. 2019;26(1):35-40.
  • McDonald HI, Thomas SL, Nitsch D. Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open. 2014;4(4):e004100.
  • Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7): 1426-37, 1437.e1-9.
  • D’Amico G, Garcia Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-31.
  • Jalan R, Fernández J, Wiest R, Schnabl B, Moreau R, Angeli P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310-24.
  • Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrosis. Liver Int. 2018;38Suppl1:126-33.
  • Tandon P, García Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrosis. Semin Liver Dis. 2008;28(1):26-42.
  • Mattos AA, Wiltgen D, Jotz RF, Dornelles CMR, Fernandes MV, Mattos ÂZ. Spontaneous bacterial peritonitis and extraperito- neal infections in patients with cirrosis. Ann Hepatol. 2020;19(5): 451-7.
  • Fernández J, Acevedo J, Castro M, García O, de Lope CR, Roca D. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55(5):1551-61.
  • Rimola A, García Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000; 32:142-53.
  • Fernández J, Tandon P, Mensa J, García Tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology. 2016;63(6):2019-31.
  • Hogea SP, Tudorache E, Fildan AP, Fira Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183-97.
  • Berenson CS, Kruzel RL, Eberhardt E, Dolnick R, Minderman H, Wallace PK. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax. 2014; 69: 811-8.
  • Rodrigo Troyano A, Suárez Cuartín G, Peiró M, Barril S, Castillo D, Sánchez Reus F. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD: Sensitive Pseudomonas aeruginosa in COPD. Respirology. 2016;21(7):1235-42.
  • Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421-38.
  • McManus TE, Marley AM, Baxter N, Christie SN, O’Neill HJ, Elborn JS. Respiratory viral infection in exacerbations of COPD. Respir Med. 2008;102:1575-80.
  • Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martínez FJ. Global Initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee Report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24-36.
  • Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-74.
  • Garcha DS, Thurston SJ, Patel ARC, Mackay AJ, Goldring JJP, Donaldson GC. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67:1075-80.
Fuente de los datos: Dialnet